ACC 2021 to highlight ‘silver lining lessons’, future challenges attributable to COVID-19
Click Here to Manage Email Alerts
The 2021 American College of Cardiology Scientific Session will be held virtually from May 15 through 17 and will feature 25 late-breaking clinical trials, 17 featured clinical research presentations and numerous abstract presentations.
“While this meeting is being delivered virtually, you will see that there have been benefits in the time to plan and also the lessons that ACC has learned in virtual education over the past year,” Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA, director of preventive cardiology, co-director of women’s heart care at the Medical University of South Carolina and chair of the 2021 ACC Scientific Session, said during a press conference. “This has come together to create a robust educational and scientific agenda. This meeting will feature everything you've come to expect from our annual scientific sessions and more.”
Meeting highlights
This year, the meeting will be delivered through a new virtual education program with the goal of improving real-time discussion between learners and faculty. Subsequently, all streamed sessions and meeting content will be made available on demand, including more than 200 talks in addition to the “Heart to Heart Conversation” podcast.
“In recent years, the Heart to Heart stage has become incredibly popular among our attendees at the meeting,” Morris said. “That was because the stage featured content that extended beyond the traditional classroom. Examples of some of those topics would include gender equity in cardiology; global perspectives on value-based care; the evolving role of advanced practice professionals in cardiovascular medicine; and one of my favorites, art as a tool for healing in cardiovascular medicine."
The following five keynote presentations will take place at the upcoming meeting:
- the Louis F. Bishop keynote with Michelle A. Albert, MO, MPH, FACC, on Saturday, May 15, at 10:30 a.m. ET: “Defining Priorities: Bringing Health Equity to the Frontlines of Cardiovascular Healthcare”;
- the Dan G. McNamara keynote with Howard A. Zucker, MD, FACC, on Sunday, May 16 at 8:00 a.m. ET: "It Happened One Day: A Personal and Professional Narrative of the Pandemic”;
- the Douglas Zipes Distinguished Young Scientist keynote with Marat Fudim, MD, on Sunday, May 17, at 9:30 a.m. ET: “Moving Volume: Splanchnic Nerve Blockade in Heart Failure”;
- the Kanu and Docey Chatterjee keynote with Nancy K. Sweitzer, MD, FACC, on Sunday, May 16 at 12:30 p.m. ET, “Futurist View of HFpEF: What Things Are Going to Look Like When We Finally Figure It All Out (And How Are We Going to Do That?)”; and
- the Eugene Braunwald keynote with Christine E. Seidman, MD, on Monday, May 17, at 12:30 p.m. ET, “Relaxation Matters: Lessons from Hypertrophic Cardiomyopathy”.
This year’s scientific session will also feature a COVID-19 intensive that will be co-chaired by David Rizik, MD, interventional cardiologist at HonorHealth in Scottsdale, Arizona, and Doreen DeFaria Yeh, MD, director of the Massachusetts General Hospital cardiovascular disease fellowship program.
“This intensive will update participants on progress, ‘silver lining’ lessons learned along with consideration of future challenges,” Morris said.
Late-breaking science
The meeting will feature 25 late breaking clinical trials across five sessions; 17 featured clinical research presentations across three sessions; and more than 3,400 abstracts for oral, moderated or poster presentation.
Late breaking science to be presented at ACC included.
- PARADISE-MI, the first head-to-head comparison of sacubitril/valsartan (Entresto, Novartis) vs. ramipril in patients with MI and reduced left ventricular ejection fraction;
- ADAPTABLE, a patient-centered trial examining the benefits and long-term effectiveness of aspirin 81 mg compared with 325 mg for secondary prevention in patients with known CVD;
- LAAOS III, an assessment of whether patients with atrial fibrillation who underwent cardiac surgery for a different reason have lower long-term risk for stroke or systemic embolism if they have concomitant surgical occlusion of the left atrial appendage performed in the same setting;
- ATLANTIC, an open label study that will compare standard of care with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) 2.5 mg twice daily or 5 mg twice daily following transcatheter aortic valve replacement; and
- DARE-19, a trial that evaluated whether dapagliflozin (Farxiga, AstraZeneca), an SGLT2 inhibitor, can help to prevent major clinical events and improve recovery in patients who are suffering from COVID-19.
Other late breaking trials to be presented include REHAB-HF, FLOWER-MI, TALOS-AMI, FIDELIO-CKD, PRADA, HOST-EXAM, RAPID-TnT, RADIANCE-HTN TRIO, CONNECT-HF, LIFE, GALACTIC-HF, PIROUETTE, CAPITAL CHILL and RAFT-AF.
Healio will be providing the latest news from the ACC Scientific Session, with physician perspective, researcher interviews and clinician insight that can be read here.
Collapse
Healio Coverage
Click Here to Manage Email Alerts